Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis

@inproceedings{Ma2009PharmacokineticsOC,
  title={Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis},
  author={Ying Ma and Bi-rong Lin and Bei Lin and Sheng Shu Hou and Wei-zhu Qian and Jing Li and Min Tan and Jian Li Ma and Bo-hua Li and Hao Wang and Ai-dong Wen and Ya-jun Guo},
  booktitle={Acta Pharmacologica Sinica},
  year={2009}
}
AbstractAim:To evaluate single-dose and multiple-dose pharmacokinetics of cytotoxic T-lymphocyte-associated antigen 4 fusion protein (CTLA4Ig) in healthy volunteers and patients with rheumatoid arthritis (RA).Methods:The clinical trials included two phase I open studies: study 1 was an open-label dose-escalation study in 27 healthy volunteers and study 2 was a single-group, open-label study in patients with rheumatoid arthritis. In study 2, 9 patients were arranged to receive 10 mg/kg of… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Pharmacokinetic study of I125-CTLA4Ig: absorption, distribution and excretion after a single intravenous administration to rat

ZG Li, J Li, +3 authors XL Wang
  • Chin J Pharm Anal
  • 2007

Abatacept (CTLA4-IG; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations

S Nadler, R Townsend, G Mikesell
  • Ann Rheum Dis 2004;
  • 2004

Biopharmaceuticals and pharmacokinetics

SL Wei, Q. Zhang
  • 2nd ed. Beijing: Peking
  • 2004

Effect of CTLA4Ig fusion protein on human T lymphocytes

Q Zhou, WZ Qian, +3 authors XD Li
  • Chin Pharmacol
  • 2002

Similar Papers

Loading similar papers…